IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine (Q37812123)

23 August 2017

title

IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine (English)

1 reference

23 August 2017

IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine (English)

1 reference

Japanese encephalitis virus

2 September 2024

main subject

0 references

0 references

1 reference

Japanese encephalitis

1 reference

1 reference

Mohan Babu Appaiahgari

series ordinal

1 reference

23 August 2017

Sudhanshu Vrati

series ordinal

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21105774

2 September 2024

publication date

1 December 2010

1 reference

full work available at URL

23 August 2017

http://www.future-drugs.com/doi/abs/10.1586/erv.10.139

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21105774

http://www.tandfonline.com/doi/pdf/10.1586/erv.10.139

2 September 2024

1 reference

Expert Review of Vaccines

2 September 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

1371-1384

1 reference

Origin and Evolution of Japanese Encephalitis Virus in Southeast Asia

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Japanese encephalitis in travelers: review of cases and seasonal risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Past, Present, and Future of Japanese Encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Antigenic structure of the Murray Valley encephalitis virus E glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Protective Mechanisms Induced by a Japanese Encephalitis Virus DNA Vaccine: Requirement for Antibody but Not CD8+ Cytotoxic T-Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

A Japanese Encephalitis Virus Peptide Present on Johnson Grass Mosaic Virus-Like Particles Induces Virus-Neutralizing Antibodies and Protects Mice against Lethal Challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Protection against Japanese encephalitis by inactivated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Side-effects with Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Allergic mucocutaneous reactions to Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Neurological complications and Japanese encephalitis vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Anaphylaxis to Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Short‐Term Safety of Live Attenuated Japanese Encephalitis Vaccine (SA14–14–2): Results of a Randomized Trial with 26,239 Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

IC51 Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

New developments in flavivirus vaccines with special attention to yellow fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

E Protein Domain III Determinants of Yellow Fever Virus 17D Vaccine Strain Enhance Binding to Glycosaminoglycans, Impede Virus Spread, and Attenuate Virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Experimental evidence that RNA recombination occurs in the Japanese encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Live flavivirus vaccines: reasons for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Arguments for live flavivirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Arguments for live flavivirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

High fidelity of yellow fever virus RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

A live, attenuated recombinant West Nile virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.139

The epidemiology of Japanese encephalitis: prospects for prevention

21 January 2018

1 reference

An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995.

2 September 2024

1 reference

Japanese encephalitis vaccines: current vaccines and future prospects

2 September 2024

1 reference

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

2 September 2024

1 reference

WHO Technical Report Series

2 September 2024

910

Yongxin

2002

1 reference

A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses

2 September 2024

1 reference

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com

2 September 2024

1 reference

Current status of flavivirus vaccines.

2 September 2024

1 reference

Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties

2 September 2024

1 reference

Arguments for live flavivirus vaccines

2 September 2024

1 reference

Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes

2 September 2024

1 reference

Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).

2 September 2024

1 reference

Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.

2 September 2024

1 reference

Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes

2 September 2024

1 reference

Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.

2 September 2024

1 reference

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

2 September 2024

1 reference

2 September 2024

Identifiers

DOI

10.1586/ERV.10.139

1 reference

release_vbopu757kba5toly2vv5himo2e

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vbopu757kba5toly2vv5himo2e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference